Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

The Role of NRAS G12D Mutations in the Response to Conventional Chemotherapy and 5-Azacitidine in Secondary AML

Andoni Garitano-Trojaola, PhD, Eva Teufel, Matteo Claudio Da Via', MD, Ana Sancho, Nadine Rodhes, Thorsten Stuehmer, Santiago Barrio Garcia, PhD, Jürgen Groll, Torsten Haferlach, MD, Raoul Tibes, Andreas Rosenwald, Hermann Einsele, MD, Martin Kortüm, MD

Blood (2018) 132 (Supplement 1): 5148.

https://doi.org/10.1182/blood-2018-99-118484

Published: 2018

Journal Articles

Targeting Cell Non-Autonomous MAPK Activation As a Novel Therapeutic Strategy in Myeloproliferative Neoplasms

Sara C. Meyer, MD PhD, Nilabh Ghosh, MSc, Simona Stivala, PhD, Anne Baerenwaldt, PhD, Hui Hao-Shen, Stefan Dirnhofer, MD, Matthias S. Dettmer, MD, Cédric Simillion, PhD, Sophia Chiu, MSc, Matthew Keller, MSc, Maria Kleppe, PhD, Morgane Hilpert, PhD, Andreas S. Buser, MD, Jakob R. Passweg, MDMS, Thomas Radimerski, PhD, Radek C. Skoda, MD, Ross L. Levine, MD

Blood (2017) 130 (Supplement 1): 381.

https://doi.org/10.1182/blood.V130.Suppl_1.381.381

Published: 2017

Journal Articles

Examination of Phosphoprotein Targets in Timed Samples from Patients with RAS -Mutated AML during Concurrent Treatment with Alpelisib and Binimetinib on the Phase Ib Clinical Trial CMEK162X2109

Kira Gritsman, MD PhD, Robert P. Hasserjian, MD, Taneisha Sinclair, David M. Weinstock, MD, Britta Will, PhD, Ulrich Steidl, MD PhD, Karen K. Ballen, MD, Amir T. Fathi, MD, Amit Verma, MD, Dejan Juric, MD, Philip C. Amrein, MD

Blood (2016) 128 (22): 2749.

https://doi.org/10.1182/blood.V128.22.2749.2749

Published: 2016

Journal Articles

Cooperative Epigenetic Remodeling By TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity

Hiroyoshi Kunimoto, MD PhD, Cem Meydan, PhD, Abbas Nazir, BS, Kaitlyn Shank, BS, Rebecca Maher, BA, Franck Rapaport, PhD, Elodie Pronier, PhD, Ari Melnick, MD, Ross L. Levine, MD, Alan H. Shih, MD PhD

Blood (2016) 128 (22): 433.

https://doi.org/10.1182/blood.V128.22.433.433

Published: 2016

Journal Articles

In Silico Modeling of Oncogenic Drivers in Waldenstrom Macroglobulinemia to Assess Additional Therapeutic Targets within the BCR Signaling Pathway Identifies MEK1/2 As a Target: Potential Therapeutic Role of Binimetinib

Aneel Paulus, MDMS, Sharoon Akhtar, MPhil, Shireen Vali, Ansu Kumar, Neeraj Kumar Singh, Shahabuddin Usmani, Himanshu Grover, Taher Abbasi, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 1279.

https://doi.org/10.1182/blood.V126.23.1279.1279

Published: 2015

Journal Articles

MEK Inhibition Is a Promising Therapeutic Strategy for MLL -Rearranged Infant ALL Patients Carrying RAS Mutations

Mark JB Kerstjens, MSc, Emma MC Driessen, MD, Merel Willekes, BSc, Sandra S Mimoso Pinhancos, MSc, Rob Pieters, MD PhD, Ronald Stam, PhD

Blood (2014) 124 (21): 919.

https://doi.org/10.1182/blood.V124.21.919.919

Published: 2014

Journal Articles

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

Frank Giles, MD MB, FRCPI, FRCPath, Sarina A. Piha-Paul, MD, Alexander I. Spira, PhD MD FACP, Fadi Braiteh, MD CPI, Julio Antonio Peguero, MD, Daniel L. Spitz, MD FACP, James A. Knost, MD, Lee Schwartzberg, MD FACP, Steven Stein, MD, August J. Salvado, MD, Claudia Lebedinsky, MD, Barinder Kang, PhD, Eric Slosberg, PhD

Blood (2014) 124 (21): 4818.

https://doi.org/10.1182/blood.V124.21.4818.4818

Published: 2014

Journal Articles

MEK1/2 Inhibition By MEK162 Is Effective Against Chronic Lymphocytic Leukaemia Cells Under Conditions That Mimic Stimulation of B-Cell Receptor-Mediated Signaling

Kyle Crassini, MBBS,BSc, William S Stevenson, MBBS, PhD, Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA, Oliver Giles Best, PhDBSc

Blood (2014) 124 (21): 3330.

https://doi.org/10.1182/blood.V124.21.3330.3330

Published: 2014

Journal Articles

MAPK-Erk1/2 Pathway Activation and Survival Of Chronic Lymphocytic Leukemia (CLL) Cells Is Induced By In Vitro Modeling Of The Tumor Microenvironment and Can Be Effectively Inhibited Using The MEK1 Inhibitor MEK162

O. Giles Best, BSc, PhD, Kyle Crassini, William s Stevenson, MBBS, PhD, Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA

Blood (2013) 122 (21): 4192.

https://doi.org/10.1182/blood.V122.21.4192.4192

Published: 2013

NARROW

The Role of NRAS G12D Mutations in the Response to Conventional Chemotherapy and 5-Azacitidine in Secondary AML

Targeting Cell Non-Autonomous MAPK Activation As a Novel Therapeutic Strategy in Myeloproliferative Neoplasms

Examination of Phosphoprotein Targets in Timed Samples from Patients with RAS -Mutated AML during Concurrent Treatment with Alpelisib and Binimetinib on the Phase Ib Clinical Trial CMEK162X2109

Cooperative Epigenetic Remodeling By TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity

In Silico Modeling of Oncogenic Drivers in Waldenstrom Macroglobulinemia to Assess Additional Therapeutic Targets within the BCR Signaling Pathway Identifies MEK1/2 As a Target: Potential Therapeutic Role of Binimetinib

MEK Inhibition Is a Promising Therapeutic Strategy for MLL -Rearranged Infant ALL Patients Carrying RAS Mutations

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

MEK1/2 Inhibition By MEK162 Is Effective Against Chronic Lymphocytic Leukaemia Cells Under Conditions That Mimic Stimulation of B-Cell Receptor-Mediated Signaling

MAPK-Erk1/2 Pathway Activation and Survival Of Chronic Lymphocytic Leukemia (CLL) Cells Is Induced By In Vitro Modeling Of The Tumor Microenvironment and Can Be Effectively Inhibited Using The MEK1 Inhibitor MEK162

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only